AKRIKHIN is one of the leading russian pharmaceutical companies

AKRIKHIN produces effective, affordable and high quality medicines in the most popular therapeutic areas in Russia

The company is in the top 5 leading local pharmaceutical producers by sales on the Russian market showing the significant growth and development rates.

akrikhin

The company’s portfolio includes about 200 products, more than 100 of them are produced at the manufacturing facility in Moscow region.

Our drugs are related to the most essential pharmacotherapeutic groups – tuberculosis, diabetes, dermatology, cardiology, neurology, gynecology, etc. and produced in total compliance with the GMP standards. 45% of products in company’s sales volume are included in the Essential Drugs List.

Previous
Next

Akrikhin is one of few Russian producers to have its own Research and Development (R&D) Center. This is a research, analysis and technological center with the very latest technical equipment and analytical instruments. The center’s main focus is generics. Taking into consideration the highly competitive generics market, Akrikhin is concentrated on developing advanced generics and also new forms of known combinations (so called “generic plus” versions). During 2014-2015 within the framework of the import substitution program the company has brought 10 products to the market.

Akrikhin manufacturing facility is a modern complex located on 36 hectares land plot, 20 km from Moscow. The facility comprises of two workshops producing finished pharmaceutical products: solid & semi-solid finished dosage forms. Production volumes are more than 80 mln packs per year. In 2011-2017 the company has realized a largescale investment program of modernization of manufacturing facility with total investments about 50 mln $.

About 1500 people work at Akrikhin, more that 800 of them are based at the manufacturing facility and 500 present company’s field force in 63 regions of Russia.

News from AKRIKHIN

The Ministry of Health of the Russian Federation has allowed simultaneous vaccination against coronavirus infection and influenza. The corresponding changes were made to the instructions for the medical use of […]

The post The Ministry of Health has allowed simultaneous vaccination against coronavirus and influenza appeared first on GxP News.

According to the instructions for the Sputnik V coronavirus vaccine published in the State Register of Medicines (GRLS), breastfeeding is no longer a contraindication for vaccination with the drug. That […]

The post The Ministry of Health approved vaccination of nursing mothers with Sputnik V appeared first on GxP News.

The Expert Council of the Industrial Development Fund approved a loan for Nanolek on Priority Projects program, according to the press center of the IDF. Nanolek, which is based in […]

The post Nanolek localizes production of active pharmaceutical substituents of HPV vaccine appeared first on GxP News.

AO Valenta Pharm pharmaceutical company is ready to provide a two-week course to all patients with multiple sclerosis (MS) who have indications for Kinesia® (Fampridine) and have a prescription for […]

The post Valenta Pharm announced the launch of its Early Access Program for the use of Kinesia® appeared first on GxP News.

Akrikhin office in Moscow

Business center CITYDEL
105064, Moscow, Zemlyanoy Val str., 9, 12 floor

Tel.: +7 (495) 721-36-97
Fax: + 7 (495) 723-72-82
E-mail: info@akrikhin.ru

Akrikhin plant in Staraya Kupavna

142450, Moscow region, Staraya Kupavna,
Kirova str., 29

Tel.: + 7 (495) 702-95-06
Fax: +7 (495) 702-95-03
E-mail: info@akrikhin.ru